Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

374 ARTÍCULOS , VIENDO DEL 286 AL 300

Blood Biomarkers for Alzheimer's Disease: Much Promise, Cautious Progress

Keshavan A, Heslegrave A, Zetterberg H, Schott JM.

Mol Diagn Ther. 2017 Feb;21(1):13-22. doi: 10.1007/s40291-016-0241-0.

Tau Imaging in Alzheimer's Disease Diagnosis and Clinical Trials

Brosch JR, Farlow MR, Risacher SL, Apostolova LG.

Neurotherapeutics. 2017 Jan;14(1):62-68. doi: 10.1007/s13311-016-0490-y.

Aberrant proteolytic processing and therapeutic strategies in Alzheimer disease

Tomita T.

Adv Biol Regul. 2017 May;64:33-38. doi: 10.1016/j.jbior.2017.01.001. Epub 2017 Jan 5.

Alzheimer's Disease and the Routine Clinical Use of CSF Biomarkers

Martorana A.

CNS Neurol Disord Drug Targets. 2017;16(4):407-413. doi: 10.2174/1871527316666170124164854.

YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer's Disease

Muszyński P, Groblewska M, Kulczyńska-Przybik A, Kułakowska A, Mroczko B.

Curr Neuropharmacol. 2017;15(6):906-917. doi: 10.2174/1570159X15666170208124324.

A second wind for the cholinergic system in Alzheimer's therapy

Douchamps V, Mathis C.

Behav Pharmacol. 2017 Apr;28(2 and 3-Spec Issue):112-123. doi: 10.1097/FBP.0000000000000300.

Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid

Bloniecki V, Aarsland D, Blennow K, Cummings J, Falahati F, Winblad B, Freund-Levi Y.

J Alzheimers Dis. 2017;57(2):387-393. doi: 10.3233/JAD-160758.

A Precision Medicine Initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling

Hampel H, O'Bryant SE, Durrleman S, Younesi E, Rojkova K, Escott-Price V, Corvol JC, Broich K, Dubois B, Lista S; Alzheimer Precision Medicine Initiative.

Climacteric. 2017 Apr;20(2):107-118. doi: 10.1080/13697137.2017.1287866. Epub 2017 Feb 9.

Metabolomic-guided discovery of Alzheimer's disease biomarkers from body fluid

Enche Ady CNA, Lim SM, Teh LK, Salleh MZ, Chin AV, Tan MP, Poi PJH, Kamaruzzaman SB, Abdul Majeed AB, Ramasamy K.

J Neurosci Res. 2017 Oct;95(10):2005-2024. doi: 10.1002/jnr.24048. Epub 2017 Mar 16.

Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial

Craft S, Claxton A, Baker LD, Hanson AJ, Cholerton B, Trittschuh EH, Dahl D, Caulder E, Neth B, Montine TJ, Jung Y, Maldjian J, Whitlow C, Friedman S.

J Alzheimers Dis. 2017;57(4):1325-1334. doi: 10.3233/JAD-161256.

Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies

Shinohara M, Tachibana M, Kanekiyo T, Bu G.

J Lipid Res. 2017 Jul;58(7):1267-1281. doi: 10.1194/jlr.R075796. Epub 2017 Apr 4.

A phase 3 trial of IV immunoglobulin for Alzheimer disease

Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH, Jack CR, Sano M, Knopman DS, Raman R, Szabo P, Gelmont DM, Fritsch S, Aisen PS; Alzheimer's Disease Cooperative Study.

Neurology. 2017 May 2;88(18):1768-1775. doi: 10.1212/WNL.0000000000003904. Epub 2017 Apr 5.

Aβ levels in the jugular vein and high molecular weight Aβ oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer's disease

Kasai T, Kondo M, Ishii R, Tanaka A, Ataka S, Shimada H, Tomiyama T, Mori H, Taylor M, Allsop D, Nakagawa M, Mizuno T, Tokuda T.

PLoS One. 2017 Apr 10;12(4):e0174630. doi: 10.1371/journal.pone.0174630. eCollection 2017.

N-glycan and Alzheimer's disease

Kizuka Y, Kitazume S, Taniguchi N.

Biochim Biophys Acta Gen Subj. 2017 Oct;1861(10):2447-2454. doi: 10.1016/j.bbagen.2017.04.012. Epub 2017 Apr 29.

Bryostatin Effects on Cognitive Function and PKCɛ in Alzheimer's Disease Phase IIa and Expanded Access Trials

Nelson TJ, Sun MK, Lim C, Sen A, Khan T, Chirila FV, Alkon DL.

J Alzheimers Dis. 2017;58(2):521-535. doi: 10.3233/JAD-170161.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias